What question did this study set out to answer?

To investigate downstream CD40 signaling pathways in B cells of patients with multiple sclerosis and evaluate how existing therapies modulate this signaling.

October 27, 2016The Journal of Immunology

CD40-Mediated NF-κB Activation in B Cells Is Increased in Multiple Sclerosis and Modulated by Therapeutics

View Full Paper

Ask AI

Bookmark

To investigate downstream CD40 signaling pathways in B cells of patients with multiple sclerosis and evaluate how existing therapies modulate this signaling.
Analyzed the phosphorylation of NF-κB and MAPKs (P38, ERK, and JNK) downstream of CD40 engagement in naive and memory B cells using multiparameter phosflow.
Compared B-cell signaling profiles between healthy donor controls and patients with relapsing-remitting multiple sclerosis (RRMS) or secondary progressive multiple sclerosis (SPMS).
Assessed changes in CD40-mediated activation following therapy with glatiramer acetate or combination therapy with interferon-beta-1a and mycophenolate mofetil.
Memory and naive B cells from patients with RRMS and SPMS exhibited significantly higher levels of phosphorylated NF-κB (p-P65) after CD40 stimulation compared to healthy donor controls.
Combination therapy with interferon-beta-1a and mycophenolate mofetil reduced CD40-stimulated P65 hyperphosphorylation in RRMS B cells to levels comparable to healthy controls, correlating with lower clinical disease activity.
Glatiramer acetate treatment independently and significantly reduced CD40-mediated P65 phosphorylation in RRMS B cells.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Translational study demonstrates elevated CD40-driven NF-κB activation in B cells from multiple sclerosis patients, suggesting a shared target for disease-modifying therapies.

Cite This Study

Ireland et al. (2016) studied this question.

synapsesocial.com/papers/6a9092c2bcd42327600d2e57 https://doi.org/10.4049/jimmunol.1600782

View Full Paper

Ask AI

Bookmark

Implication

Translational study demonstrates elevated CD40-driven NF-κB activation in B cells from multiple sclerosis patients, suggesting a shared target for disease-modifying therapies.

CD40-Mediated NF-κB Activation in B Cells Is Increased in Multiple Sclerosis and Modulated by Therapeutics

Key Points

Discussion

Implication

Cite This Study

CD40-Mediated NF-κB Activation in B Cells Is Increased in Multiple Sclerosis and Modulated by Therapeutics

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider